AINDEX
Markets

IN8bio, Inc. (INAB)

INABNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)

$0.7997

-0.0203 (-2.48%) today

Closed, Nov 16, 4:00 PM ET

-2.48% 1D
Market cap
$8.86m
P/E
–
EPS, last 4 quarters
$-1.01
Dividend yield
–
Day range
–
52-week range
$0.8000 to $2.73
Average volume
–
Previous close
$0.8200

Analysts

3 covering

Buy2 buy, 1 hold, 0 sell

Targets a year out average $5.50, +587.8% from here

$5.00now $0.7997$6.00

Earnings

next estimate $-0.6500

Next report

Dec 2025

-44.4%

Mar 2026

+55.9%

Jun 2026

+59.0%

Sep 2026

+57.9%

estimate reported, and the surprise

Financials

QuarterSep 2025Dec 2025Mar 2026Jun 2026
Revenue––––
Gross profit––––
Operating income-$3.97m-$5.03m-$5.27m-$4.93m
Net income-$3.85m-$4.94m-$5.09m-$4.78m

News

8 latest

The company

IN8bio is a clinical-stage biopharmaceutical company developing T cell and T cell engager (TCE) product candidates to address unmet medical needs. T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's pipeline is anchored by INB-600, a novel T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also developing INB-100, an allogeneic T cell therapy candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified T cell therapy candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.in8bio.com.

Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ-CM
Region
North America
Website
in8bio.com

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.